Effectiveness of periodontal therapy in HIV-seropositive patients with chronic periodontitis undergoing highly-active antiretroviral therapy

• Conditions: K05.3; Chronic periodontitis

• Registration Number: DRKS00000097
• Lead Sponsor: niversität Witten/HerdeckeGeschäftführungWissenschaftliche Direktion

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07-28
• Study Completion: 2013-01-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Systematic periodontla therapy in 2003
-HIV-seropositive status (only test group)
-Antiretroviral therapy with immunoreconstitution (only test group)
-Informed consent

Exclusion Criteria

-Additional systemic diseases associated with periodontal disease (e.g. diabetes mellitus)
-Intake of drugs, that may lead to gingival hyperplasia (e.g. anticonvulsants)
-No informed consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Target variable: Retention of teeth<br><br>Parameter: tooth in situ<br>Scheduled: 5 yrs postoperative<br>Methode: clinical oral examination<br>Instrument: eye, x-ray

Secondary Outcome Measures

Name	Time	Method
Target parameter I: Microbial load<br><br>Parameter: Periodontal pathogens<br>Schedule: 5 yrs postoperative<br>Method: DNA-Chip<br>Instrument: ParoCheck10<br><br><br>Target parameter II: Attachment level<br><br>Parameter: Pocket probing depth and recession<br>Schedule: 5 yrs postoperative<br>Method: clinical examination<br>Instrument: WHO periodontal probe<br><br>Target parameter III: Marginal inflammation<br><br>Parameter: Bleeding on probing of the marginal gingiva<br>Schedule: 5 yrs postoperative<br>Method: Bleeding on probing<br>Instrument: WHO periodontal probe